Effects of HMB Supplementation on Recovery Following ACL Surgery
Launched by METABOLIC TECHNOLOGIES INC. · Nov 10, 2015
Trial Information
Current as of April 24, 2025
Completed
Keywords
ClinConnect Summary
Beta-hydroxy-beta-methylbutyrate (HMB) is a nutritional supplement shown to improve muscle mass with exercise, and also in muscle loss conditions caused by a decrease in physical activity. Participants will be recruited who will undergo reconstructive surgery for a complete ACL tear and will then enter a standard physical therapy program during a six week recovery period. Subjects will receive either HMB or a placebo supplement during the recovery period. Muscle mass will be measured two weeks prior to the surgery and again after the recovery period using an InBody 720 body composition anal...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Complete anterior cruciate ligament (ACL) tear
- • Will benefit from ACL reconstructive surgery
- • Are able to participate in the physical therapy program
- • No previous major knee injuries or surgeries
- • No health conditions affecting muscle mass
- Exclusion Criteria:
- • Incomplete ACL tear
- • Have multiple or bilateral ligament tears
- • Are unable to participate in the physical therapy program
- • Have had previous major knee injuries or surgeries
- • Have health conditions affecting muscle mass
Trial Officials
John A Rathmacher, PhD
Principal Investigator
Metabolic Technologies Inc.
About Metabolic Technologies Inc.
Metabolic Technologies Inc. is a pioneering biotechnology company dedicated to advancing metabolic health through innovative research and development of therapeutic solutions. With a focus on harnessing the potential of metabolic pathways, the company conducts rigorous clinical trials aimed at addressing metabolic disorders and enhancing overall well-being. Committed to scientific excellence and patient-centric approaches, Metabolic Technologies Inc. collaborates with leading researchers and healthcare professionals to translate cutting-edge discoveries into effective treatments that improve quality of life for individuals affected by metabolic conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ames, Iowa, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials